China’s drugs offer lifeline for global pharma as it peers over the patent cliff
Out-licensing of clinical candidates from China has increased dramatically over the last five years, as the world’s pharma companies shore…
Out-licensing of clinical candidates from China has increased dramatically over the last five years, as the world’s pharma companies shore…
In the midst of the rising popularity of glucagon-like peptide-1 receptor agonists (GLP-1RAs), and their compounded versions, the US Food…
Last month, the head of the US Food and Drug Administration's (FDA) Centre for Drug Evaluation and Research (CDER) George…
Foundational certainties of the biopharma industry may no longer hold true for the sector’s future as paradigm shifts reshape the…
As pharma companies continue to license candidates developed in China, experts say a particular licensing model is allowing the country's…
Stalled negotiations around the UK's Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG) between the UK government and…
In the wake of their seismic ascension over the lucrative weight loss market, glucagon-like peptide-1 receptor agonists (GLP-1RAs) are facing…
In a bid to chase competitiveness, the EU is advancing its most drastic revision of pharmaceutical law in 20 years.…
Johnson & Johnson (J&J) has unveiled first-in-human data on its trispecific antibody that demonstrates a 100% response rate in a…
A November 2025 PDUFA date has been set for Kura Oncology’s oral acute myeloid leukaemia (AML) drug ziftomenib following the…